Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A mixture of low-molecular-weight neuropeptides and amino acids derived from purified pig brain proteins. Approved as a drug in over 50 countries (including much of Europe and Asia) for stroke, traumatic brain injury, and Alzheimer's disease. One of the most clinically studied neuropeptide preparations in the world.
A synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation and Gerontology — the same institution behind Epitalon. Pinealon is designed to target the central nervous system and pineal gland, with research focused on neuroprotection, cognitive function, and circadian rhythm regulation.
Acts as a neurotrophic factor, mimicking the effects of BDNF, NGF, and other endogenous growth factors. Promotes neuronal survival, synaptic plasticity, and neurogenesis. Reduces excitotoxicity and oxidative stress in neural tissue. Crosses the blood-brain barrier due to its small molecular weight.
Penetrates the blood-brain barrier and accumulates in neurons. Modulates gene expression related to neuronal survival and function. Reduces oxidative stress in neural tissue. Appears to regulate melatonin synthesis through pineal gland activity, supporting circadian rhythm normalization.
- Stroke recovery and rehabilitation
- Traumatic brain injury recovery
- Alzheimer's disease (approved in some countries)
- Cognitive enhancement
- Neuroprotection
- Cognitive enhancement and memory
- Neuroprotection
- Sleep quality improvement
- Age-related cognitive decline
- Stroke recovery support (preliminary research)
- Derived from porcine brain — religious/ethical considerations for some
- Injection site reactions
- Rare allergic reactions
- Seizure risk at high doses (rare)
- Not FDA-approved — quality of gray-market sources varies significantly
- Very limited independent Western research
- Most studies from Russian institutions
- Long-term safety unknown
- Mechanism not fully characterized
- Injection site reactions
Not FDA-approved in the United States. Approved as a prescription drug in 50+ countries including Germany, Austria, Russia, China, and most of Eastern Europe and Asia. Available in the US only as a research chemical or through international sources. Has the most robust clinical evidence base of any compound in the nootropic peptide category.
Not FDA-approved and not on any compounding list. Available as a research chemical. Research base is almost entirely from Russian institutions — independent replication is limited. Not affected by the 2026 regulatory changes.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.